ProCE Banner Activity

New Directions With PARP Inhibitors in Pancreatic Cancer

Podcast Episodes
Listen to Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitors that are being investigated for the treatment of pancreatic cancer.

Released: February 21, 2022

Expiration: February 20, 2023

No longer available for credit.

Share

Faculty

Eileen O Reilly

Eileen O Reilly, MD

Associate Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Naureen Starling

Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

Associate Director of Clinical Research
Reader
Department of GI Cancers
The Royal Marsden Hospital/ICR
Consultant Medical Oncologist, GI Cancers
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Eileen O Reilly, MD

Associate Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Eileen M. O’Reilly, MD, has disclosed that she has received funds for research support from Agios, Arcus, AstraZeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, and Yiviva and consulting fees from Adicet, Alnylam, AstraZeneca, Autem, Bayer, BeiGene, Berry Genomics, Celgene, Cend, CytomX, Eisai, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Lilly, Merck, Nerviano, QED, Rafael, Redhill, Servier, Silenseed, Sobi, Surface Oncology, Therabionics, Vector, and Yiviva.

Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

Associate Director of Clinical Research
Reader
Department of GI Cancers
The Royal Marsden Hospital/ICR
Consultant Medical Oncologist, GI Cancers
London, United Kingdom

Naureen Starling, MD, FRCP, has disclosed that she has received consulting fees from Amgen, GSK, Lilly, MSD, Novartis, Pierre Fabre, and Servier.